Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Acute Lymphoblastic Leukemia
100%
Blast Cells
14%
Central Nervous System Cells
14%
Central Nervous System Relapse
14%
Clinical Outcomes
100%
Complete Remission
71%
Conventional Chemotherapy
14%
Cranial Irradiation
42%
Cyclophosphamide
14%
Cytarabine
14%
Doxorubicin
14%
Effective Method
14%
Erythrocyte Receptor
14%
Immunoglobulin
14%
Institutional Control
14%
Intrathecal
42%
Isolated Central Nervous System
14%
Leukemia
14%
Leukocyte Count
14%
Mediastinal Mass
14%
Mercaptopurine
42%
Methotrexate
100%
New Risks
14%
Relapse Rate
14%
Remission Duration
28%
Remission Induction
14%
Risk Criteria
14%
Sequential Chemotherapy
14%
Sheep Erythrocytes
14%
Teniposide
14%
Total Therapy
100%
Treatment Group
14%
Unfavorable Prognosis
14%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
100%
Blast Cell
7%
Central Nervous System
15%
Chemotherapy
15%
Cyclophosphamide
7%
Cytarabine
7%
Doxorubicin
7%
Infusion
7%
Leukocyte
7%
Lymphocyte Membrane Immunoglobulin
7%
Mediastinum Mass
7%
Mercaptopurine
23%
Methotrexate
100%
Oral
15%
Receptor
7%
Recurrence Risk
7%
Sheep Erythrocyte
7%
Skull Irradiation
23%
Spontaneous Remission
7%
Teniposide
7%
Treatment Group
7%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Lymphoblastic Leukemia
100%
Chemotherapy Regimens
15%
Cyclophosphamide
7%
Cytarabine
7%
Doxorubicin
7%
Intrathecal
23%
Lymphocyte Membrane Immunoglobulin
7%
Mediastinum Mass
7%
Mercaptopurine
23%
Methotrexate
100%
Receptor
7%
Recurrence Risk
7%
Remission
46%
Sheep
7%
Teniposide
7%
Treatment Group
7%
Immunology and Microbiology
Blast Cell
7%
Central Nervous System
15%
Cyclophosphamide
7%
Leukocyte Count
7%
Lymphocyte Membrane Immunoglobulin
7%
Methotrexate
100%
Sheep Erythrocyte
7%